Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
-Aphios Corporation today announced that it is spinning-off Aphios Pharma to develop FDA- approved, cannabis-based drugs for treating highly unmet Central Nervous System disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
-Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King`s College London. Professor David E. Thurston of the Institute of Pharmaceutical Science is leading the team at King`s to develop and opti
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
Webcast Available at http://www.BioCorRx.comAnaheim, CA 02/23/2017 BioCorRx Inc., a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided an update on the preclinical development of BICX101, a new sustained release injectable naltrexone product for the treatment of substance abuse addic
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
LONDON, UK/ ACCESSWIRE/ February 23, 2017/ Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. as the Company announced on February 22, 2017, that the Company's New Drug Application resubmission for DEXTENZA?, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
By a News Reporter-Staff News Editor at Gene Therapy Weekly- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc., reported that the FDA has granted Fast Track designation for the Phase 3 clinical investigation of Generx cardiovascular angiogenic gene therapy as a one-time treatment for improving exercise...
Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the first patient has been dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007, the Company s gene therapy candidate for the treatment of Recessive Dystro
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration in recurrent C. difficile infections. OpenBiome has transformed the standard of care for C. diffici
Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure Item 7.01 Regulation FD Disclosure. On February 23, 2017, Flex Pharma, Inc. (the Company) will present a poster entitled Flex-201: A Multicenter, Randomized, Blinded Study to Evaluate the Efficacy and Tolerability of FLX-787 in MS at the Americas Committee for Treatme
Flexion Therapeutics, Inc. today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate Zilretta in patients with osteoarthritis of the knee. The open-label study is expected to enroll approximately 200 patients at up to 20 clinical sites in the United S
Novartis International AG/ Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC. *FDA also grants Breakthrough Therapy designation based on Phase III data in. brain* If approved in the first-line setting, Zykadia will offer previously untreated ALK+ metastatic NSCLC patients a new treatment op
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisais global Oncology Business Group, announced today that Peter G. Smith, Ph.D., will become the companys chief scientific officer, effective March 1, 2017. In his role as chief scientific officer, Dr.
Calgary, Alberta- Imaging Dynamics Company Ltd. is pleased to announce that it received notification today that the United States Food and Drug Administration has granted Market Clearance approval for its new Digital Radiography product line- Aquarius 8600 1717 TC and Aquarius 8600 1417 TC. These products utilize and integrate into IDC s proprie
IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system for the treatment of cancer and inflammatory disease, today announced the appointment of seven leading physicians to its clinical advisory board. We are delighted to welcome this accomplished and distinguished